...
ocs-img

Oculis Holding AG Ordinary shares, Common Stock

OCS

NMQ

$17.07

+$0.08

(0.47%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$705.72M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
35.94K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.01
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$10.11 L
$18 H
$17.07

About Oculis Holding AG Ordinary shares, Common Stock

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameOCSSectorS&P500
1-Week Return0.35%2.44%2.58%
1-Month Return11.06%-4.49%0.09%
3-Month Return40.84%-8.82%4.76%
6-Month Return44.05%-4.46%9.89%
1-Year Return55.18%3.16%26.47%
3-Year Return75.98%-0.83%25.98%
5-Year Return75.98%35.65%86.34%

Financials

Dec '20Dec '21Dec '22Dec '23
Total Revenue993.00K960.00K912.00K883.00K[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":96.68,"profit":true},{"date":"2022-12-31","value":91.84,"profit":true},{"date":"2023-12-31","value":88.92,"profit":true}]
Cost of Revenue9.34M9.57M22.22M29.25M[{"date":"2020-12-31","value":31.92,"profit":true},{"date":"2021-12-31","value":32.71,"profit":true},{"date":"2022-12-31","value":75.99,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit(8.34M)(8.61M)(21.31M)(28.36M)[{"date":"2020-12-31","value":-834400000,"profit":false},{"date":"2021-12-31","value":-860800000,"profit":false},{"date":"2022-12-31","value":-2131200000,"profit":false},{"date":"2023-12-31","value":-2836400000,"profit":false}]
Gross Margin(840.28%)(896.67%)(2336.84%)(3212.23%)[{"date":"2020-12-31","value":-840.28,"profit":false},{"date":"2021-12-31","value":-896.67,"profit":false},{"date":"2022-12-31","value":-2336.84,"profit":false},{"date":"2023-12-31","value":-3212.23,"profit":false}]
Operating Expenses12.34M13.23M32.38M52.35M[{"date":"2020-12-31","value":23.56,"profit":true},{"date":"2021-12-31","value":25.28,"profit":true},{"date":"2022-12-31","value":61.85,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(12.34M)(13.23M)(32.38M)(80.71M)[{"date":"2020-12-31","value":-1233600000,"profit":false},{"date":"2021-12-31","value":-1323200000,"profit":false},{"date":"2022-12-31","value":-3237600000,"profit":false},{"date":"2023-12-31","value":-8071400000,"profit":false}]
Total Non-Operating Income/Expense(5.07M)(10.39M)(12.58M)(7.87M)[{"date":"2020-12-31","value":-507200000,"profit":false},{"date":"2021-12-31","value":-1039200000,"profit":false},{"date":"2022-12-31","value":-1258300000,"profit":false},{"date":"2023-12-31","value":-786700000,"profit":false}]
Pre-Tax Income(14.79M)(18.52M)(38.64M)(88.69M)[{"date":"2020-12-31","value":-1479000000,"profit":false},{"date":"2021-12-31","value":-1852400000,"profit":false},{"date":"2022-12-31","value":-3864300000,"profit":false},{"date":"2023-12-31","value":-8869500000,"profit":false}]
Income Taxes83.00K27.00K55.00K107.00K[{"date":"2020-12-31","value":77.57,"profit":true},{"date":"2021-12-31","value":25.23,"profit":true},{"date":"2022-12-31","value":51.4,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Income After Taxes(14.87M)(18.55M)(38.70M)(88.80M)[{"date":"2020-12-31","value":-1487300000,"profit":false},{"date":"2021-12-31","value":-1855100000,"profit":false},{"date":"2022-12-31","value":-3869800000,"profit":false},{"date":"2023-12-31","value":-8880200000,"profit":false}]
Income From Continuous Operations(14.87M)(18.55M)(38.70M)(88.80M)[{"date":"2020-12-31","value":-1487300000,"profit":false},{"date":"2021-12-31","value":-1855100000,"profit":false},{"date":"2022-12-31","value":-3869800000,"profit":false},{"date":"2023-12-31","value":-8880200000,"profit":false}]
Income From Discontinued Operations----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(14.87M)(18.55M)(38.70M)(88.80M)[{"date":"2020-12-31","value":-1487300000,"profit":false},{"date":"2021-12-31","value":-1855200000,"profit":false},{"date":"2022-12-31","value":-3869800000,"profit":false},{"date":"2023-12-31","value":-8880200000,"profit":false}]
EPS (Diluted)-0.100.04(2.71)[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":40,"profit":true},{"date":"2023-12-31","value":-2710,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

OCS
Cash Ratio 3.81
Current Ratio 4.02

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

OCS
ROA (LTM) -33.46%
ROE (LTM) -69.33%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

OCS
Debt Ratio Lower is generally better. Negative is bad. 0.24
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.76

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

OCS
Trailing PE NM
Forward PE NM
P/S (TTM) 813.05
P/B 6.66
Price/FCF NM
EV/R 0.00
EV/Ebitda NM

FAQs

What is Oculis Holding AG Ordinary shares share price today?

Oculis Holding AG Ordinary shares (OCS) share price today is $17.07

Can Indians buy Oculis Holding AG Ordinary shares shares?

Yes, Indians can buy shares of Oculis Holding AG Ordinary shares (OCS) on Vested. To buy Oculis Holding AG Ordinary shares from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in OCS stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Oculis Holding AG Ordinary shares be purchased?

Yes, you can purchase fractional shares of Oculis Holding AG Ordinary shares (OCS) via the Vested app. You can start investing in Oculis Holding AG Ordinary shares (OCS) with a minimum investment of $1.

How to invest in Oculis Holding AG Ordinary shares shares from India?

You can invest in shares of Oculis Holding AG Ordinary shares (OCS) via Vested in three simple steps:

  • Click on Sign Up or Invest in OCS stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Oculis Holding AG Ordinary shares shares
What is Oculis Holding AG Ordinary shares 52-week high and low stock price?

The 52-week high price of Oculis Holding AG Ordinary shares (OCS) is $18. The 52-week low price of Oculis Holding AG Ordinary shares (OCS) is $10.11.

What is Oculis Holding AG Ordinary shares price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Oculis Holding AG Ordinary shares (OCS) is

What is Oculis Holding AG Ordinary shares price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Oculis Holding AG Ordinary shares (OCS) is 6.66

What is Oculis Holding AG Ordinary shares dividend yield?

The dividend yield of Oculis Holding AG Ordinary shares (OCS) is 0.00%

What is the Market Cap of Oculis Holding AG Ordinary shares?

The market capitalization of Oculis Holding AG Ordinary shares (OCS) is $705.72M

What is Oculis Holding AG Ordinary shares’s stock symbol?

The stock symbol (or ticker) of Oculis Holding AG Ordinary shares is OCS

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top